Treatment-related myelodysplasia following fludarabine combination chemotherapy

Haematologica

Volumn 91, Issue 11, 2006, Pages 1546-1550

  Tam, Constantine S ^a,b   Seymour, John F ^a,c   Prince, H Miles ^a   Kenealy, Melita ^a   Wolf, Max ^a   Januszewicz, E Henry ^a   Westerman, David ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukemia; Follicular lymphoma; Purine analog; Waldenstr m's macroglobulinemia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DNA REPAIR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; VIDARABINE;

EID: 33750958028     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT Jr. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988;71:403-14.
2. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.
3. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
4. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-4.
5. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71.
6. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-25.
7. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432-8.
8. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454-60.
9. Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000;18:773-9.
10. Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10:28-32.
11. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-9.
12. Sandoval A, Consoli U, Plunkett: W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996;2:1731-41.
13. Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 2004;100:2181-9.
14. Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412-20.
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
16. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7:1975-86.
17. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludaradine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell Lymphomas - Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004;104:3064-71.
18. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002;119:976-84.
19. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878-84.
20. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon α. Blood 2005;105:4573-5.